A Study of Pemetrexed Plus Cisplatin With Concurrent Radiation Therapy Followed by Docetaxel Consolidation in Patients With Inoperable Squamous Cell Lung Cancer

Inclusion Criteria: * Newly diagnosed stage IIIA/ IIIB squamous cell lung cancer; * All sites of disease must be amenable to definitive radiotherapy; * Age 18 years to 75 years; * Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2; * Forced expiratory volume in 1 second(FEV1)\> 0.75L; * No previous chest radiotherapy, immunotherapy or biotherapy; * Adequate bone marrow, liver and renal function, as specified below: Absolute Neutrophil Count (ANC) ≥ 1.5 x 109/L; Hemoglobin ≥ 8 g/dL; Platelets ≥ 100 x 109/L; Serum total bilirubin ≤ 1.5 x upper limit of normal (ULN) ; Aspartate transaminase(AST) and alanine Transaminase(ALT) ≤ 2.5 x ULN or ≤ 5 x ULN if liver metastases are present; Serum creatinine ≤ 1.5 x upper limit of normal or creatinine clearance ≥ 60ml/min for patients with creatinine levels above institutional normal. * For women of child-bearing potential, negative pregnancy test within 14 days prior to starting treatment * Men and women of childbearing age must be willing to use effective contraception while on treatment and for at least 3 months thereafter; * Patients and their family signed the informed consents; Exclusion Criteria: * Active infection; * History of significant cardiac disease (unstable angina, congestive heart failure, myocardial infarction within the previous 6 months, ventricular arrhythmias); * Malnutrition (loss of ≥ 20% of the original body weight); * Performance status: 3-4; * Sensor or motor neuropathy \> grade I; * Second primary malignancy, except for non-melanoma skin cancer; * Psychiatric illness or social situation that would preclude study compliance; * Pregnant or lactating women.